Form 4: Teva Exec Hughes Reports RSU Vesting, Tax-Related Share Sale

Eric A. Hughes, EVP of Global R&D and Chief Medical Officer at Teva Pharmaceutical Industries, reported the vesting of restricted share units and a subsequent sale of shares to cover tax obligations.

Summary

• Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical Industries Ltd., reported transactions that occurred on March 4, 2026.
• Hughes acquired 23,251 Ordinary Shares upon the vesting of Restricted Share Units (RSUs) from a grant made on March 4, 2024.
• Concurrently, 23,251 Restricted Share Units were disposed of due to their vesting.
• Hughes sold 11,277 Ordinary Shares at a weighted average price of $32.4645 to cover tax withholding obligations in connection with the RSU vesting.
• The sale price for these shares ranged from $32.095 to $33.30 per share.
• Hughes also received a new grant of 50,643 Restricted Share Units on March 4, 2026, which will vest in tranches from March 4, 2027, to March 4, 2030.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there's a sale of shares, it's for tax purposes and offset by a new RSU grant, indicating ongoing executive commitment and compensation.

Positives

• The vesting of 23,251 Restricted Share Units indicates the fulfillment of compensation milestones for Eric A. Hughes.
• A new grant of 50,643 Restricted Share Units demonstrates continued long-term incentive alignment between the executive and the company's future performance.

Negatives

• The sale of 11,277 Ordinary Shares, although for tax withholding, reduces the executive's direct equity ownership in the company.

Future Outlook

The new grant of Restricted Share Units to Eric A. Hughes, vesting through March 2030, indicates a long-term incentive structure designed to align executive interests with future company performance.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity awards like Restricted Share Units, is a standard practice across the pharmaceutical industry to incentivize long-term performance and retain key talent. The use of a Rule 10b5-1 plan for tax-related sales is also a common and compliant method for insiders to manage their equity holdings.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and generally has minimal direct impact on shareholders, especially when part of a 10b5-1 plan. The new RSU grant aligns executive incentives with long-term shareholder value.
• Employees: No direct impact on general employees.

Next Steps

• Future vesting of 23,251 Restricted Share Units on March 4, 2027, from the 2024 grant.
• Future vesting of 23,252 Restricted Share Units on March 4, 2028, from the 2024 grant.
• Future vesting of 12,660 Restricted Share Units on March 4, 2027, March 4, 2028, and March 4, 2029, from the 2026 grant.
• Future vesting of 12,663 Restricted Share Units on March 4, 2030, from the 2026 grant.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically RSU vesting and a tax-related share sale, along with a new RSU grant. These transactions are pre-planned and do not indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Restricted Share Units, RSU Vesting, Share Sale, Executive Compensation, Eric A. Hughes, Rule 10b5-1 Plan